Phase II trial of bortezomib plus doxorubicin in hepatocellular carcinoma (E6202): a trial of the Eastern Cooperative Oncology Group.

Ciombor KK, Feng Y, Benson AB, Su Y, Horton L, Short SP, Kauh JS, Staley C, Mulcahy M, Powell M, Amiri KI, Richmond A, Berlin J
Invest New Drugs. 2014 32 (5): 1017-27

PMID: 24890858 · PMCID: PMC4171216 · DOI:10.1007/s10637-014-0111-8

MeSH Terms (19)

Adult Aged Antineoplastic Combined Chemotherapy Protocols Boronic Acids Bortezomib Carcinoma, Hepatocellular Chemokine CCL5 Cytokines Disease-Free Survival Doxorubicin Female Humans Liver Neoplasms Male Middle Aged Pyrazines Treatment Outcome Vascular Endothelial Growth Factor A Young Adult

Connections (4)

This publication is referenced by other Labnodes entities: